Panacea Biotec Ltd
Panacea Biotec was set up in the year 1984, under the name of Panacea Drugs Private Limited and was publicly listed in the year 1995. Panacea Biotec is a research based Biotechnology company doing Research and Development, Manufacturing, Sales, Distribution and Marketing of Pharmaceuticals, Vaccines and Biosimilars.
- Market Cap ₹ 868 Cr.
- Current Price ₹ 142
- High / Low ₹ 202 / 114
- Stock P/E
- Book Value ₹ 138
- Dividend Yield 0.00 %
- ROCE -10.3 %
- ROE -10.9 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Stock is trading at 1.03 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -4.95% over past five years.
- Contingent liabilities of Rs.640 Cr.
- Earnings include an other income of Rs.82.7 Cr.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
710 | 608 | 510 | 687 | 653 | 544 | 593 | 457 | 544 | 625 | 661 | 460 | 552 | |
773 | 665 | 582 | 643 | 541 | 505 | 509 | 591 | 490 | 548 | 674 | 558 | 571 | |
Operating Profit | -63 | -56 | -72 | 44 | 112 | 39 | 84 | -134 | 54 | 77 | -13 | -98 | -20 |
OPM % | -9% | -9% | -14% | 6% | 17% | 7% | 14% | -29% | 10% | 12% | -2% | -21% | -4% |
-15 | -7 | 183 | 28 | 70 | 62 | 8 | 338 | -14 | 9 | 1,687 | 154 | 83 | |
Interest | 101 | 104 | 150 | 105 | 127 | 101 | 101 | 105 | 174 | 185 | 181 | 4 | 4 |
Depreciation | 77 | 86 | 71 | 67 | 73 | 68 | 57 | 54 | 43 | 46 | 44 | 39 | 37 |
Profit before tax | -255 | -253 | -111 | -99 | -19 | -67 | -66 | 45 | -178 | -146 | 1,449 | 13 | 22 |
Tax % | 21% | 7% | -2% | -3% | -10% | 16% | -15% | 17% | -9% | -1% | 26% | 363% | |
-206 | -234 | -113 | -108 | -21 | -56 | -76 | 38 | -194 | -148 | 1,078 | -34 | -12 | |
EPS in Rs | -33.55 | -38.22 | -18.29 | -17.38 | -2.98 | -8.89 | -12.07 | 6.15 | -31.69 | -24.09 | 175.91 | -5.42 | -1.99 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | -3% |
5 Years: | -5% |
3 Years: | -5% |
TTM: | 17% |
Compounded Profit Growth | |
---|---|
10 Years: | 5% |
5 Years: | -6% |
3 Years: | 12% |
TTM: | 76% |
Stock Price CAGR | |
---|---|
10 Years: | -1% |
5 Years: | -5% |
3 Years: | -26% |
1 Year: | 18% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | -11% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
Reserves | 869 | 620 | 507 | 449 | 426 | 350 | 303 | 344 | 161 | -235 | 871 | 837 | 841 |
Preference Capital | 0 | 0 | 0 | 16 | 16 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
877 | 979 | 1,060 | 1,095 | 1,088 | 994 | 941 | 646 | 742 | 820 | 34 | 20 | 21 | |
198 | 235 | 371 | 381 | 334 | 440 | 349 | 379 | 481 | 587 | 848 | 407 | 404 | |
Total Liabilities | 1,950 | 1,839 | 1,943 | 1,930 | 1,854 | 1,789 | 1,598 | 1,376 | 1,390 | 1,178 | 1,759 | 1,271 | 1,272 |
1,195 | 1,154 | 1,276 | 1,144 | 1,071 | 1,001 | 949 | 806 | 657 | 609 | 622 | 600 | 624 | |
CWIP | 91 | 135 | 172 | 155 | 161 | 30 | 40 | 23 | 24 | 34 | 17 | 42 | 52 |
Investments | 33 | 22 | 16 | 15 | 9 | 7 | 7 | 5 | 6 | 0 | 5 | 13 | 34 |
631 | 527 | 479 | 616 | 614 | 750 | 602 | 542 | 703 | 534 | 1,114 | 615 | 562 | |
Total Assets | 1,950 | 1,839 | 1,943 | 1,930 | 1,854 | 1,789 | 1,598 | 1,376 | 1,390 | 1,178 | 1,759 | 1,271 | 1,272 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
228 | -24 | 54 | 37 | 91 | 131 | 118 | 105 | -30 | 107 | -108 | -422 | |
-124 | -61 | -38 | -37 | 16 | -26 | 55 | -6 | -35 | -48 | 1,283 | 430 | |
-134 | 105 | -30 | -1 | -117 | -107 | -164 | -101 | 91 | -47 | -1,176 | -18 | |
Net Cash Flow | -29 | 20 | -14 | -1 | -10 | -2 | 9 | -2 | 26 | 12 | -2 | -10 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 35 | 42 | 68 | 52 | 79 | 95 | 84 | 71 | 46 | 49 | 45 | 48 |
Inventory Days | 405 | 371 | 375 | 404 | 516 | 770 | 651 | 173 | 344 | 311 | 296 | 292 |
Days Payable | 128 | 243 | 430 | 272 | 318 | 607 | 540 | 572 | 463 | 440 | 327 | 256 |
Cash Conversion Cycle | 311 | 170 | 13 | 184 | 278 | 259 | 195 | -328 | -73 | -80 | 14 | 83 |
Working Capital Days | 112 | 92 | -113 | 31 | 134 | 82 | 6 | -307 | 97 | 6 | -229 | -7 |
ROCE % | -8% | -8% | -8% | 0% | 4% | 2% | 3% | -16% | 4% | 6% | -6% | -10% |
Documents
Announcements
- Certificate Pursuant To Regulation 40(9) Of SEBI (LODR) Regulations, 2015 For The Financial Year Ended March 31, 2024 13 Apr
-
Demat Status Report For The Month Ended March 31, 2024
5 Apr - No share has been dematerialised during the month of March, 2024. A copy of the certificate obtained from the Company''s RTA viz. Skyline Financial Services …
- Compliance Certificate Under Regulation 7(3) Of The SEBI (LODR) Regulations, 2015 For The Financial Year Ended On March 31, 2024 5 Apr
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
5 Apr - Certificate dated April 03, 2024, issued by Skyline Financial Services Pvt. Ltd. RTA of the Company, confirming compliance under Regulation 74(5) of SEBI (Depositories and …
-
Announcement under Regulation 30 (LODR)-Change in Directorate
1 Apr - Mr. Krishna Murari Lal, Mr. Namdeo Narayan Khamitkar and Mr. Raghava Lakshmi Narsimhan have completed their second and final terms of five consecutive years as …
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from nse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Highlights[1]
a. Being WHO-prequalified, the Company is one of the leading supplier of vaccines to Government of India, UNICEF & PAHO^ since more than two decades.
b. One of the leading domestic pharmaceutical formulations player with brands in super specialty and chronic care segments - Organ Transplantation, Oncology and Diabetes
c. 3 ANDAs approved by USFDA, 6 ANDAs submitted and awaiting approval from USFDA
d. 34 Active Patents globally and 21 Patent applications under process
e. Total 74 Brands of which 70 are for Pharma and 4 for Vaccines
f. 11 brands in domestic markets of which Pharma – 10; Vaccine – 1